Top Retinal Biologics Companies

Global Retinal Biologics Market size was valued at USD 22.9 billion in 2023 and is poised to grow from USD 24.64 billion in 2024 to USD 44.27 billion by 2032, growing at a CAGR of 7.6% during the forecast period (2025-2032). 

Several players such as Pharmaceuticals and Roche hold large market shares with well-established portfolios of retinal biologic drugs. These industry players basically lead research, development and commercialization efforts, which contributes to a consolidated market presence. On the same way, smaller biotechnology firms and startups play an important role in niche areas of retinal biologic research, representing fragmentation. This mix of established market leaders and emerging new companies encourages competition and drive innovation within the industry. 'F. Hoffmann-La Roche Ltd (Switzerland) ', 'Regeneron Pharmaceuticals Inc. (USA) ', 'AbbVie Inc. (USA) ', 'Novartis AG (Switzerland) ', 'Bayer AG (Germany) ', 'Amgen Inc. (USA) ', 'Johnson & Johnson (USA) ', 'Biogen Inc. (USA) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Bristol-Myers Squibb Company (USA) ', 'Sanofi Genzyme (France) ', 'Santen Pharmaceutical Co., Ltd. (Japan) ', 'Bausch & Lomb Incorporated (USA) ', 'Adverum Biotechnologies, Inc. (USA) ', 'MeiraGTx Holdings plc (UK) ', 'Oxurion NV (Belgium) ', 'Kodiak Sciences Inc. (USA) ', 'Clearside Biomedical, Inc. (USA) ', 'Neurotech Pharmaceuticals, Inc. (USA) ', 'Opthea Limited (Australia)', '​In March 2024, Roche Pharma India, a part of the Swiss pharmaceutical company Roche, unveiled its highly anticipated medication called Vabysmo (faricimab) in India. This drug is pointed toward treating neovascular or "wet" age-related macular degeneration (nAMD) and diabetic macular edema (DME), which are two significant reasons for vision loss globally.', 'In September 2023, the European Commission gave its approval for the first biosimilar of aflibercept. There will be an ongoing expansion of biosimilar offerings worldwide, which enhances their current portfolio in oncology and diabetes. This will positively impact patients in the EU who are dealing with muscular degeneration and diabetic retinopathy.', 'In July 2023, Bausch & Lomb completed an acquisition of the Blink over the counter line (OTC) of eye drops from Johnson & Johnson Vision. This has widened company’s range of OTC eye care products thus allowing them to offer improves convenience to consumers.'

In the United States, based on the information from centers for Disease Control and Prevention millions of individuals were diagnosed with diabetic retinopathy. Additionally, among these individuals some were identified with prone to developing retinopathy that could harm their vision. Diabetic retinopathy, which in turn is on the rise in America. The growing prevalence is anticipated to drive up the demand for treatments, mostly leading to increased market growth in the country.

Genetic Treatment Approaches: There have been recent advances in gene therapy research for retinal diseases such as inherited retinal dystrophies are transforming the development and use of retinal biologic drugs.

The North America region has the highest revenue share in the global retinal biologics market. This is because more individuals are affected by retinal diseases, particularly among those with diabetes. This led to an increase in demand for treatments, which is a major driver of market expansion. In the United States, there are millions of people which are affected with diabetic retinopathy, which is a leading cause of vision impairment. This widespread occurrence creates a substantial market for treatment solutions. Additionally, some major companies are implementing strategic initiatives such as introducing new products, establishing partnerships and engaging in acquisitions. All these actions have contributed to the market's growth. For instance, Novartis obtained FDA approval for a novel treatment targeting diabetic macular edema, while Genentech's application for a treatment addressing various retinal diseases received FDA acceptance. If one combined these factors, North America emerges as a promising market for retinal biology with expectations of continued growth in the upcoming future.